Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2023 07:30 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a...
September 06, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company...
September 05, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
August 30, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
August 29, 2023 06:58 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research...
August 22, 2023 16:43 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in...
August 04, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
July 31, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

Generated total U.S. net product revenues of $89.6 million, including $67.3 million for SYFOVRE® (pegcetacoplan injection) and $22.3 million for EMPAVELI® (pegcetacoplan)SYFOVRE reduced nonsubfoveal...
July 30, 2023 13:00 ET | Source: Apellis Pharmaceuticals, Inc.

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safety profile of SYFOVRE in GALE was consistent with...
July 29, 2023 14:52 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more...